ClinicalTrials.gg
RecruitingNCT06992843LAPTOPSUpdated Nov 19, 2026

Neuroprotection Bundles For Comatose Survivors Following Cardiac Arrest

An interventional study of Goal-directed care bundle for neuroprotection and Usual Care in Cardiac Arrest and Post-cardiac Arrest Care, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Xiangya Hospital of Central South University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,008
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Heart Arrest with a site in China — 17 open to participants now, 22 under way, none of them phase 3. Heart Arrest · China.

Started
2025
with 5 others
No phase
5 of 37
2 open now
Primary completion
2027-08
later than 12 of 21 live
Registered
32nd of 37
by date

Among the 37 studies in Heart Arrest with a site in China, this one is one of 6 that started in 2025, is one of 5 with no phase, reaches primary completion later than 12 of the 21 other live ones, and was the 32nd registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

17 of the 37 studies in Heart Arrest with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Heart Arrest with a site in China, or all of them as a file.
02

Study summary

The investigators designed LAPTOPS to determine the effectiveness of a goal-directed neuroprotection bundles of active management including body temperature,PaCO2,PaO2,position,Blood glucose ,blood sodium,Blood pressure and Lactate vs. usual care in adult post-cardiac arrest care.

LAPTOPS is a large-scale pragmatic clinical trial to provide reliable evidence over the effectiveness of a widely applicable goal-directed care bundle in acute phase of adult post-cardiac arrest care.

03

Conditions studied

  • Cardiac Arrest
  • Post-cardiac Arrest Care

Browse trials for

Keywords

  • post-cardiac arrest care
  • neuroprotection
  • cardiac arrest
  • Care Bundle
  • Clinical Trial
  • Stepped-wedge Cluster
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years and \< 80 years
  • Patients of in-hospital or out-of-hospital cardiac arrest who have returned -spontaneous circulation (ROSC) after cardiopulmonary resuscitation and do not require CPR for more than 20 minutes;
  • Patients who are unconscious after ROSC, defined as FOUR motor response score \< 4 points or GSC ≤ 8 points;
  • Family members or legal representatives signed .

Exclusion criteria

Exclusion Criteria:

  • Unwitnessed cardiac arrest, estimated time from cardiac arrest to start of CPR > 30 minutes;
  • Time from cardiac arrest to ROSC > 60 minutes;
  • Patients who woke up immediately after ROSC by CPR;
  • End-stage diseases;
  • Cardiac arrest considered to be caused by neurological diseases;
  • The patient was in a vegetative state before cardiac arrest;
  • The interval from the onset of cardiac arrest to enrollment is >72 hours .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
1,008 participants (estimated)

Study arms

  • Other
    Goal-directed care bundle for neuroprotection

    Management policy to receive a goal-directed care bundle that involves the rapid correction (\<24 hour) of physiological variables as soon as the abnormality is recognised and for the control to be maintained in patients for 72h or hospital discharge (or death, if sooner)

    Other: Goal-directed care bundle for neuroprotection

  • Other
    Usual care group

    Patients receive the usual management based on local guidelines and hospital's individual policy.

    Other: Usual Care

Interventions

  • OtherGoal-directed care bundle for neuroprotection

    Reducing lactate (Lac) to \<2 mmol/L within 24 hours.Maintaining systolic arterial pressure at 120-140 mmHg. Elevating the head-of-bed to 30 degrees. Maintaining body temperature ≤37.7°C. Maintaining PaO₂ at 70-100 mmHg. Maintaining PaCO₂ at 35-45 mmHg. Maintaining blood glucose at 7.8-10.0 mmol/L. Maintaining serum sodium level at 140-150 mmol/L. If any management parameter falls outside the target range, immediate correction is required within 24 hours of enrollment and must be sustained for 72 hours. Given the dynamic nature of some targets (e.g., mean arterial pressure, body temperature), a degree of flexibility is permitted in achieving these goals. Patients are considered to have successfully implemented the neuroprotection bundle if the achievement rate of individual targets is ≥80% and all targets are met. The medications(antipyretics, vasopressor agents) is acceptable to achieve these targets.

  • OtherUsual Care

    Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.

06

What researchers measure

Primary outcomes

  1. Favorable neurological prognosis

    Assessed using the CPC score, with a score of 1-2 being a favorable outcome.

    Time frame: 90 days post cardiac arrest

Secondary outcomes

  1. GCS score

    GCS score

    Time frame: 7 days post cardiac arrest

  2. CPC score

    CPC score

    Time frame: 1 day (discharge date)

  3. GCS score

    GCS score

    Time frame: 1 day (discharge date)

  4. Time to death

    Number of days alive within 180 days from ROSC.

    Time frame: 180 days

  5. the length of ICU stay

    the length of ICU stay

    Time frame: The total length of IC-stay will be determined from the date of ICU admission until the patient is discharged from the Intensive Care Unit or the date of death from any cause, assessed up to 1 year after the first day of admission.

  6. the length of hospital stay

    the length of hospital stay

    Time frame: The total length of hospital-stay will be determined from the date of ICU admission until the patient is discharged from the hospital or the date of death from any cause assessed up to 1 year after the first day of admission.

  7. the length of mechanical ventilation

    the length of mechanical ventilation

    Time frame: Total ventilation time during ICU stay will be determined when the patient is discharged from the ICU or when the patient past away from any cause, assessed up to 1 year after the first day of admission.

  8. the incidence of adverse event

    The incidence of adverse effects during ICU treatment

    Time frame: From the date of ICU admission until the patient is discharged from the Intensive Care Unit or the date of death from any cause, assessed up to 1 year after the first day of admission.

  9. in-hospital mortality

    in-hospital mortality

    Time frame: The total length of hospital-stay will be determined from the date of ICU admission until the patient is discharged from the hospital or the date of death from any cause assessed up to 1 year after the first day of admission.

  10. 28-day mortality

    28-day mortality

    Time frame: 28 days post cardiac arrest

  11. Quality of life assessment

    Health-related Quality of Life - EQ-5D (Index value)

    Time frame: 90 days post cardiac arrest

  12. bundle compliance rate

    referring to the proportion of patients whose management parameters are within the target ranges.

    Time frame: 72 hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2027, 22 months after the start.

Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 22 months is below that.

Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2025
First posted
May 28, 2025
StartActual
Oct 22, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and responsible party
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06992843
Responsible party
Lina Zhang, MD, PhD (Professor, Xiangya Hospital of Central South University) — Principal investigator
First posted
May 28, 2025
Start date
Oct 22, 2025
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Lina Zhang
Contact
zln7095@163.com
86+15874875763

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion